• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型恶唑烷酮类药物AZD2563与其他八种药物的抗厌氧活性比较。

Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.

作者信息

Ednie Lois M, Jacobs Michael R, Appelbaum Peter C

机构信息

Department of Pathology, Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.

出版信息

J Antimicrob Chemother. 2002 Jul;50(1):101-5. doi: 10.1093/jac/dkf088.

DOI:10.1093/jac/dkf088
PMID:12096013
Abstract

The anti-anaerobic activity of AZD2563, a new oxazolidinone, was compared with that of eight other agents against 201 Gram-positive and 99 Gram-negative anaerobes. MIC(50) and MIC(90) values (mg/L) for the 201 Gram-positive organisms were as follows: AZD2563, 1.0/4.0; linezolid, 1.0/4.0; quinupristin/dalfopristin, 0.5/1.0; amoxicillin, 0.25/1.0; clindamycin, 0.25/8.0; metronidazole, 0.5/>16.0; vancomycin, 0.5/2.0; teicoplanin, 0.125/0.25; and meropenem, 0.06/1.0. AZD2563, linezolid, vancomycin, teicoplanin and quinupristin/dalfopristin were mainly active against Gram-positive anaerobes, with no useful activity against Gram-negative anaerobes.

摘要

将新型恶唑烷酮类药物AZD2563的抗厌氧活性与其他八种药物针对201株革兰氏阳性厌氧菌和99株革兰氏阴性厌氧菌的抗厌氧活性进行了比较。201株革兰氏阳性菌的MIC(50)和MIC(90)值(mg/L)如下:AZD2563,1.0/4.0;利奈唑胺,1.0/4.0;奎奴普丁/达福普汀,0.5/1.0;阿莫西林,0.25/1.0;克林霉素,0.25/8.0;甲硝唑,0.5/>16.0;万古霉素,0.5/2.0;替考拉宁,0.125/0.25;美罗培南,0.06/1.0。AZD2563、利奈唑胺、万古霉素、替考拉宁和奎奴普丁/达福普汀主要对革兰氏阳性厌氧菌有活性,对革兰氏阴性厌氧菌无有效活性。

相似文献

1
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.新型恶唑烷酮类药物AZD2563与其他八种药物的抗厌氧活性比较。
J Antimicrob Chemother. 2002 Jul;50(1):101-5. doi: 10.1093/jac/dkf088.
2
Activity of linezolid against anaerobic bacteria.利奈唑胺对厌氧菌的活性。
Int J Antimicrob Agents. 2003 Jul;22(1):28-34. doi: 10.1016/s0924-8579(03)00087-6.
3
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.新型恶唑烷酮类药物RBX 7644(瑞苯唑酮)与其他八种药物的抗厌氧菌活性比较。
Antimicrob Agents Chemother. 2003 Mar;47(3):1143-7. doi: 10.1128/AAC.47.3.1143-1147.2003.
4
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.新型大环化合物OPT-80与其他八种药物针对特定厌氧菌种的活性比较。
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4. doi: 10.1128/AAC.48.11.4430-4434.2004.
5
Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.新型恶唑烷酮类药物AZD2563与其他九种药物的抗肺炎球菌活性比较。
J Antimicrob Chemother. 2002 Jul;50(1):95-100. doi: 10.1093/jac/dkf080.
6
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.美罗培南对具有临床重要性厌氧菌的生长抑制特性。
J Antimicrob Chemother. 1989 Sep;24 Suppl A:119-24. doi: 10.1093/jac/24.suppl_a.119.
7
In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.新型恶唑烷酮类药物AZD2563针对罕见革兰氏阳性菌的体外评估。
Diagn Microbiol Infect Dis. 2002 Feb;42(2):119-22. doi: 10.1016/s0732-8893(01)00329-7.
8
Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.长效恶唑烷酮类药物AZD2563的初步药敏试验指南
Int J Antimicrob Agents. 2004 Jan;23(1):6-10. doi: 10.1016/j.ijantimicag.2003.05.007.
9
Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.XRP 2868、原始霉素、奎奴普丁-达福普汀、万古霉素、达托霉素、利奈唑胺、克拉霉素、替利霉素、克林霉素和氨苄西林对厌氧革兰氏阳性菌、放线菌和乳酸杆菌的体外活性比较
Antimicrob Agents Chemother. 2005 Jan;49(1):408-13. doi: 10.1128/AAC.49.1.408-413.2005.
10
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.达托霉素、利奈唑胺和奎奴普丁/达福普汀对某大型癌症中心革兰氏阳性菌分离株的体外活性比较
Diagn Microbiol Infect Dis. 2005 Jul;52(3):255-9. doi: 10.1016/j.diagmicrobio.2005.02.015.

引用本文的文献

1
The antimicrobial activity of linezolid against unconventional pathogens.利奈唑胺对非传统病原体的抗菌活性。
PeerJ. 2025 Feb 12;13:e18825. doi: 10.7717/peerj.18825. eCollection 2025.
2
In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.新型恶唑烷酮类药物DA-7867对近期需氧菌和厌氧菌临床分离株的体外活性
Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. doi: 10.1128/AAC.48.1.352-357.2004.
3
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
新型恶唑烷酮类药物RBX 7644(瑞苯唑酮)与其他八种药物的抗厌氧菌活性比较。
Antimicrob Agents Chemother. 2003 Mar;47(3):1143-7. doi: 10.1128/AAC.47.3.1143-1147.2003.